Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003051602 | SCV003343313 | likely benign | Hereditary breast ovarian cancer syndrome | 2022-04-15 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004948929 | SCV005548673 | uncertain significance | Hereditary cancer-predisposing syndrome | 2024-08-01 | criteria provided, single submitter | clinical testing | The c.7401T>G variant (also known as p.A2467A), located in coding exon 13 of the BRCA2 gene, results from a T to G substitution at nucleotide position 7401. This nucleotide substitution does not change the alanine at codon 2467. This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive, and direct evidence is insufficient at this time (Ambry internal data). Based on the available evidence, the clinical significance of this variant remains unclear. |